Skip to main content

European Screening Centre; Unique Library for Attractive Biology

Objective

By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner).

ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.

Field of science

  • /social sciences/economics and business/economics/sustainable economy

Call for proposal

H2020-JTI-IMI2-2017-12-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

STICHTING LYGATURE
Address
Jaarbeursplein 6
3521 AL Utrecht
Netherlands
Activity type
Other
EU contribution
€ 1 434 943,75

Participants (19)

PIVOT PARK SCREENING CENTRE BV
Netherlands
EU contribution
€ 7 128 756,25
Address
Kloosterstraat 9
5349 AB Oss
Activity type
Research Organisations
BIOASCENT DISCOVERY LIMITED
United Kingdom
EU contribution
€ 6 475 450
Address
Bo Ness Road
ML1 5UH Newhouse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TAROS CHEMICALS GMBH & CO KG
Germany
EU contribution
€ 292 600
Address
Emil-figge-str. 76A
44227 Dortmund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 491 230
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
EDELRIS SAS
France
EU contribution
€ 292 600
Address
Avenue Lacassagne 115
69003 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SYGNATURE DISCOVERY LIMITED
United Kingdom
EU contribution
€ 292 600
Address
Pennyfoot Street Biocity
NG1 1GF Nottingham
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SYNCOM BV
Netherlands
EU contribution
€ 292 600
Address
Kadijk 3
9747 AT Groningen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF DUNDEE
United Kingdom
EU contribution
€ 1 256 612,50
Address
Nethergate
DD1 4HN Dundee
Activity type
Higher or Secondary Education Establishments
BAYER AKTIENGESELLSCHAFT
Germany
EU contribution
€ 0
Address
Kaiser-wilhelm-allee 1
51373 Leverkusen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASTRAZENECA AB
Sweden
EU contribution
€ 0
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GRUNENTHAL GMBH
Germany
EU contribution
€ 0
Address
Zieglerstrasse 6
52078 Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JANSSEN PHARMACEUTICA NV
Belgium
EU contribution
€ 0
Address
Turnhoutseweg 30
2340 Beerse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
Germany
EU contribution
€ 0
Address
Frankfurter Strasse 250
64293 Darmstadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SANOFI-AVENTIS DEUTSCHLAND GMBH
Germany
EU contribution
€ 0
Address
Bruningstrasse 50
65929 Frankfurt Am Main
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DE RECHERCHES SERVIER
France
EU contribution
€ 0
Address
3 Rue De La Republique
92150 Suresnes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UCB BIOPHARMA SRL
Belgium
EU contribution
€ 0
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Medicines for Malaria Venture
Switzerland
EU contribution
€ 0
Address
Route De Pre Bois 20 Icc Building Block G 20
1215 Geneve
Activity type
Research Organisations
MERCATORIAL BV
Netherlands
EU contribution
€ 265 243,75
Address
Kerkenbos 1013
6546 BB Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MERCALEADS BV
Netherlands
EU contribution
€ 27 356,25
Address
Kerkenbos 1013
6546 BB Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)